Neumora 10-Q Confirms Going-Concern Doubt on $85.7M Cash
NMRA sits 33% above its 52-week low of $0.315 on light trading volume (0.3× avg).
Summary
Neumora's Q3 10-Q confirms substantial doubt about its ability to continue as a going concern, with $85.7 million of cash insufficient to fund operations for twelve months and no updated runway guidance.
Key Events · Earnings and Guidance · NMRA
-
Going-Concern Warning Confirmed
Neumora states that $85.7 million of cash and equivalents at September 30, 2026 will not fund operating plans for at least twelve months from the issuance date, concluding substantial doubt exists about its ability to continue as a going concern.
-
Loss Narrows on Cost Cuts
Q3 net loss was $34.4 million versus $56.8 million a year earlier, as R&D fell to $22.6 million from $40.5 million and G&A to $10.8 million from $12.2 million; the nine-month net loss was $131.0 million versus $177.5 million.
-
Thin Equity, Leveraged Balance Sheet
Total stockholders' equity is $18.6 million against a $1,315.1 million accumulated deficit, with $54.0 million of K2HV term loan principal outstanding at a 13.8% effective rate and a minimum liquidity covenant effective July 1, 2026.
-
ATM Is the Funding Source
Neumora raised $22.2 million net in the nine months ended September 30, 2026 under its $300.0 million at-the-market sales agreement with Leerink, and says it will require substantial additional funding.
Analysis · NMRA · Life Sciences
The Q3 8-K gave the headline numbers; this 10-Q states the conclusion plainly. With $85.7 million of cash at September 30, 2026, Neumora says available liquidity will not fund operations for at least twelve months and that substantial doubt exists about its ability to continue as a going concern. Management declined to give runway guidance and says the company will need substantial additional funding, which in practice means more equity or debt. Against that backdrop the balance sheet is thin: $18.6 million of total stockholders' equity, a $1,315.1 million accumulated deficit, and a $54.0 million K2HV term loan carrying a 13.8% effective rate with a minimum liquidity covenant that took effect July 1, 2026. The company has been leaning on its $300 million ATM, raising $22.2 million net in the first nine months of 2026, and the stock already trades below $1.00, triggering an October 26, 2026 Nasdaq minimum-bid notice with a 180-day cure window. Cost cuts are real — Q3 R&D fell to $22.6 million from $40.5 million and the net loss narrowed to $34.4 million from $56.8 million — but they buy time, not a solution.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NMRA was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.6M. The 52-week trading range was $0.32 to $3.65. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.